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Abstract The activating BRAFV600 mutation is a well-
established negative prognostic biomarker in metastatic colo-
rectal carcinoma (CRC). A recently developed monoclonal
mouse antibody (clone VE1) has been shown to detect reliably
BRAFV600E mutated protein by immunohistochemistry (IHC).
In this study, we aimed to compare the detection of BRAFV600E
mutations by IHC, Sanger sequencing (SaS), and ultra-deep
sequencing (UDS) in CRC. VE1-IHC was established in a
cohort of 68 KRAS wild-type CRCs. The VE1-IHC was only
positive in the three patients with a known BRAFV600E muta-
tion as assessed by SaS and UDS. The test cohort consisted of
265 non-selected, consecutive CRC samples. Thirty-nine out of
265 cases (14.7 %) were positive by VE1-IHC. SaS of 20
randomly selected IHC negative tumors showed BRAF wild-
type (20/20). Twenty-four IHC-positive cases were confirmed
by SaS (24/39; 61.5 %) and 15 IHC-positive cases (15/39;
38.5 %) showed a BRAF wild-type by SaS. UDS detected a
BRAFV600E mutation in 13 of these 15 discordant cases. In one
tumor, the mutation frequency was below our threshold for
UDS positivity, while in another case, UDS could not be
performed due to low DNA amount. Statistical analysis
showed sensitivities of 100 % and 63 % and specificities of
95 and 100% for VE1-IHC and SaS, respectively, compared to
combined results of SaS and UDS. Our data suggests that there
is high concordance between UDS and IHC using the anti-
BRAFV600E (VE1) antibody. Thus, VE1 immunohistochemis-
try is a highly sensitive and specific method in detecting
BRAFV600E mutations in colorectal carcinoma.
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Introduction
Colorectal carcinoma (CRC) is the third most malignant neo-
plasm in males and second most in females worldwide [1]. In
a metastasized stage, the 5-year survival rate decreases to less
than 10 % [2]. A combined systemic therapy including
cetuximab, a monoclonal anti-EGFR antibody, increases the
overall and progression-free survival in tumors bearing a wild-
type ofKRAS (‘Kirsten rat sarcoma viral oncogene homolog’)
and BRAF (‘v-raf murine sarcoma viral oncogene homolog
B1’) genes [3, 4]. In contrast, mutated BRAF is a marker of
worse prognosis in CRC [5–7]. The most common genetic
change in the BRAF gene of CRC is a c.1799 T > A point
mutation in Exon 15, causing an amino acid exchange from
valine to glutamic acid (p.V600E), which leads to a 10-fold
increased kinase activity [8–10].
Usually, analysis of the BRAFV600E status is performed using
different polymerase chain reaction (PCR)-based detection
methods like Sanger sequencing, pyrosequencing, and qPCR.
Besides the average costs of approximately $300 per analysis
[11, 12], these techniques are time consuming and require a
high-quality laboratory infrastructure with well-trained staff.
Currently, Sanger sequencing is probably the most often used
technique because of its reliability and high specificity.
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However, its sensitivity usually does not allow detecting muta-
tions below a frequency of 15–20 % tumor cells [13, 14].
Among other more sensitive techniques, next-generation
sequencing technology overcomes this disadvantage and re-
veals low-frequency mutations in heterogeneous tumor popu-
lations. Recently, we demonstrated the reliability of this tech-
nique as a standard procedure in diagnostics of CRC using
genomicDNA isolated from formalin-fixed paraffin-embedded
tissues (FFPE) [15].
In contrast, immunohistochemistry is a tissue-based, cost-
effective technique, which is easy to perform and routinely
available in most pathology laboratories [16]. Capper et al.
[17] developed a monoclonal mouse antibody (clone VE1),
which recognizes the BRAFV600E protein. Several studies
have shown that this antibody reliably detects BRAFV600E
mutations in malignant neoplasms by immunohistochemistry
in routinely processed FFPE tissues [18–26].
In our study, we aimed to evaluate the reliability of this new
antibody in detecting BRAFV600E mutations compared to con-
ventional Sanger sequencing in a cohort of consecutive CRCs.
Furthermore, we aimed to assess the sensitivity of the anti-
body below the detection limit of Sanger sequencing by
including ultra-deep sequencing (UDS).
Materials and methods
Patients
For this study, tumor tissue, and tissue microarray (TMA)
slides from two cohorts were analyzed. We have previously
described a cohort of 68 KRAS wild-type CRCs [15]. Among
these 68 KRAS wild-type CRCs, we identified three tumors
with BRAFV600E mutations as assessed by Sanger sequencing
(SaS) and UDS. All cases were diagnosed at the Institute of
Surgical Pathology, University Hospital Zurich (Switzerland)
between 2006 and 2011. The median age was 61 ranging from
35 to 83. Nineteen patients were females and 49 males.
The test cohort consisted of non-selected, consecutive CRC
samples of 265 patients, diagnosed at the Institute of Surgical
Pathology, University Hospital Zurich between 2001 and
2011. The age ranged from 21 to 95 years (median 72 years).
Both sexes were equally distributed (133 females, 132 males).
The study was approved by the Cantonal Ethics Committee of
Zurich (KEK-ZH-NR: 2010-0093/0).
Tissue microarray construction
Original hematoxylin and eosin stained sections of all CRC
samples were retrieved from the archives of the Institute of
Surgical Pathology, University Hospital Zurich and reviewed
by two histopathologists (antibody establishment cohort: J.R.,
H.M.; test cohort: M.S., A.W.). The TMAs were constructed
with core replicas as described elsewhere [27]. In brief, two
tissue cores (diameter 0.6 mm) of a representative tumor area
of each patient were taken from a “donor” block and arranged
in a new “recipient” block using a custom-built instrument.
Each recipient block also included 14 colon cancer cell lines
with known BRAF mutational status (six cell lines with a
BRAFV600E mutation, eight cell lines with BRAF wild-type),
which served as controls. Recipient blocks of the test cohort
additionally include normal colorectal tissue of CRC patients
as additional control tissue.
Immunohistochemistry
Immunohistochemistry (IHC) was conducted on 2-μm thick
sections of both TMAs with Ventana Benchmark XT automat-
ed staining system (Ventana Medical Systems, Tucson, AZ,
USA) and according to the manufacturer's instructions. Briefly,
after antigen retrieval with cell conditioner 1 (Ventana Medical
Systems) for 64 min and pre-primary peroxidase inhibition, the
TMA slides were incubated with BRAFV600E antibodies (clone
VE1, dilution 1:200; Spring Bioscience, Pleasanton, USA) for
32 min at 37 °C. After that, incubation with OptiView DAB
IHCDetection Kit (VentanaMedical Systems) followed. Slides
were counterstained with hematoxylin and Bluing reagent for
4 min each. The reaction quality was controlled using cell lines
on the TMAs with known BRAFV600E mutational status. The
immunostained slides were independently evaluated by two
pathologists (M.S. and M.Rö.), both blinded to the BRAF
mutation status. TMA spots lacking of tumor tissue were
excluded from the analysis. According to the unequivocal
cytoplasmic staining of a majority of the tumor cells, TMA
spots were ranked into three staining categories: score 0 for
negative, score 1 for weakly/moderately positive, and score 2
for strongly positive. Of each case, the strongest immunoreac-
tivity of the two spots was counted.
DNA extraction
Three tissue cylinders (diameter 0.6 mm) were punched from
formalin-fixed, paraffin-embedded (FFPE) tissue block of
each CRC patient. After extraction of genomic DNA using
DNeasy Blood & Tissue Kit 250 (Qiagen, Hilden, Germany),
DNA-quantification was done with NanoDrop.
Sanger sequencing
Sanger sequencing evaluating the mutational status of BRAF
exon 15 was done for all IHC-positive and for 20 IHC-
negative cases of the test cohort. DNA was PCR amplified
(AmpliTaq Gold, Roche, Switzerland) using the primers de-
scribed in Table 1. The cycling conditions were 5 min at
95 °C, 40 cycles each with 1 min at 95 °C, 1 min at 53 °C,
1 min at 72 °C and a final elongation step of 10 min at 72 °C.
624 Virchows Arch (2013) 463:623–631
PCR products were purified using the Qiagen MiniElute PCR
Purification Kit (Qiagen) and sequenced with a Genetic
Analyzer 3130xl (Applied Biosystems) using the same
primers mentioned above. A change of the electropherogram
was classified as mutation, if the peak of the aberrant base (i)
was clearly above background, (ii) was present in forward and
reverse direction, and (iii) its height exceeded more than 10 %
of the reference base peak height. Examples for Sanger se-
quencing declared as wild-type are shown in Supplementary
Figure S1. As a comparison of a “true” mutation, co40 is
depicted as positive control in Supplementary Figure S1.
Ultra-deep sequencing (UDS)
Additional UDS was performed to assess the BRAF status in
all cases of the test cohort, which showed discordant results
after IHC and Sanger sequencing. The UDS procedure is
described elsewhere [15]. Shortly, an independent PCR with
fusion primers including multiplex identifiers (MIDs)
(Table 1) was performed from the same DNA sample used
for Sanger sequencing. Amplicon processing was done as
described by the Amplicon Library Preparation and emPCR
(Lib-A) Method GS Junior Titanium Series manual from
Roche. 500,000 enriched beads were loaded on a 454 Junior
Sequencer (Roche). Demultiplexing and variant calling was
done with the Amplicon Variant Analyzer v2.7 (AVA) soft-
ware from Roche. Selection criteria (at least 50 reads contain-
ing the mutation and at least 0.38 % mutation frequency) for a
true positive variant are described in Rechsteiner et al. [15].
Statistics
The calculation of the IHC VE1 sensitivity, specificity, and
positive (PPV) and negative predictive value (NPV) including
their 95 % confidence intervals (CI) by comparison with the
combined results of both sequencing methods as “gold stan-
dard” was performed using Microsoft Excel 2010 (Microsoft
Corporation, Redmond, USA). Measurement of interobserver
agreement was performed using SPSS 20.0 (IBM Corporation,
Armonk, USA).
Results
BRAFV600E (VE1) antibody establishment
Immunohistochemistry of cell line controls showed moderate
positivity in one and strong positivity in five of the six known
BRAFV600E mutated cell lines, while all eight cell lines with
known BRAF wild-type were immunohistochemically
completely negative. A representative staining of the cell lines
is shown in Supplementary Figure S2.
The BRAFV600E (VE1) antibody was further established in
68 KRAS wild-type CRCs with three (4.4 %) BRAFV600E
mutations previously identified by SaS and UDS. All three
BRAFV600E mutated CRC were immunohistochemically pos-
itive and showed strong staining reactivity with the VE1
antibody. Some CRCs showed an uncharacteristic weak to
strong staining in the intracellular mucus of signet ring-like
cells. In the upper row of Fig. 1, one CRCwith such a staining
pattern is depicted with its Sanger sequence on the right panel
without visible mutation. Another CRC with strong staining
is presented in the lower row of Fig. 1 with its correspond-
ing sequence. Due to the fact that no BRAF mutation could
be detected in both CRCs by sequencing, all similar
stainings in the intracellular mucus of signet ring-like cells
were classified as artifacts and scored negative. All other
cases were unequivocally negative, resulting in a sensitivity
Table 1 Primers used for Sanger sequencing and ultra-deep sequencing of BRAF exon 15
Sequencing Primer
Sanger sequencing
BRAF Ex.15 F 5'-TCATAATGCTTGCTCTGATAGGA-3'
BRAF Ex.15 R 5'-GGCCAAAAATTTAATCAGTGGA-3'
Ultra-deep sequencing a
BRAF 15 F_MID1 5'-CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGTTCATAATGCTTGCTCTGATAGGA-3'
BRAF 15 R_MID1 5'-CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGTGGCCAAAAATTTAATCAGTGGA-3'
BRAF 15 F_MID2 5'-CGTATCGCCTCCCTCGCGCCATCAGACGCTCGACATCATAATGCTTGCTCTGATAGGA-3'
BRAF 15 R_MID2 5'-CTATGCGCCTTGCCAGCCCGCTCAGACGCTCGACAGGCCAAAAATTTAATCAGTGGA-3'
BRAF 15 F_MID3 5'-CGTATCGCCTCCCTCGCGCCATCAGAGACGCACTCTCATAATGCTTGCTCTGATAGGA-3'
BRAF 15 R_MID3 5'-CTATGCGCCTTGCCAGCCCGCTCAGAGACGCACTCGGCCAAAAATTTAATCAGTGGA-3'
BRAF 15 F_MID4 5'-CGTATCGCCTCCCTCGCGCCATCAGAGCACTGTAGTCATAATGCTTGCTCTGATAGGA-3’
BRAF 15 R_MID4 5'-CTATGCGCCTTGCCAGCCCGCTCAGAGCACTGTAGGGCCAAAAATTTAATCAGTGGA-3’
Ex exon, F forward, R reverse
a Italic letters in primers: ultra-deep sequencing adapters with multiplex identifiers (MIDs)
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and specificity of 100 % each. There was a perfect
interobserver agreement with a kappa value of 1.000.
VE1 expression in colorectal carcinoma of the test cohort
Both observers agreed on the interpretation of the VE1 im-
munohistochemical staining in all but five cases (three cases:
score 0 vs. score 1; two cases: score 1 vs. score 2) resulting in a
kappa value of 0.921 (p <0.01). After discussion, a consensus
was obtained. One case was not evaluable because of loss of
tumor material during staining process. Of the remaining 264
cases, 225 (85.2 %) were immunohistochemically negative,
19 (7.2 %) showed an IHC-score 1, and 20 (7.6 %) an IHC-
score 2 (Fig. 2).
BRAF mutational analysis by Sanger sequencing in colorectal
carcinoma of the test cohort
These 39 positive cases as well as 20 randomly selected IHC-
negative tumors were submitted to BRAFV600E mutation
Fig. 1 Unspecific staining of tissue by VE1-IHC. Moderate (score 1,
upper row) and strong (score 2, lower row) staining of intracellular mucus
in signet ring-like cells (original magnifications: left panel×10, middle
panel×40) and nuclei of normal surface epithelium. The right panel shows
the corresponding wild-type Sanger sequences. Arrows indicate the loca-
tion of the T/A (forward strand) mutation leading to BRAFV600E
Fig. 2 VE1 immunohistochemistry of different colorectal carcinoma of the test cohort with score 0 (a ×40 original magnification), score 1 (b ×40), and
score 2 (c×40) for VE1-immunohistochemistry
626 Virchows Arch (2013) 463:623–631
analysis. SaS of the 20 randomly chosen IHC-negative cases
confirmed the immunohistochemical results and showed no
mutation in exon 15 of the BRAF gene. Of the 19 IHC-score 1
cases, SaS showed a BRAFV600E mutation in 13 cases and a
BRAF wild-type situation in six tumors. Among the 20 IHC-
score 2 cases, SaS resulted in 11 BRAFV600E mutated and in
nine wild-type cases (Fig. 3).
BRAF mutational analysis by Ultra-deep sequencing
in colorectal carcinoma of the test cohort
UDS was performed in 14 IHC-positive cases, which were
BRAF wild-type by SaS. The DNA amount was too low for
analysis in one case. Additionally, one case with IHC-score 1
in one TMA core (site 1) and IHC-score 2 on the second TMA
core (site 2) was also included in the UDS analysis.
Interestingly, DNA extraction from site 1 and subsequent
SaS detected a BRAF mutation in the core with IHC-score 1
and none in the DNA extracted from site 2. Therefore, UDS
was performed with the DNA derived from site 2 to investi-
gate whether a low frequency mutation was missed by SaS.
Moreover, a positive control was included in the UDS analy-
sis, in which SaS detected a BRAFV600E mutation.
In Fig. 4a, the total number of reads from the UDS analysis,
including mutated and wild-type BRAF sequences, is shown
per patient (mean 7,077 reads). In Fig. 4b, the fraction of reads
with BRAFV600E mutations is depicted (mean 449 reads). In 14
cases, a BRAFV600E mutation was detected by UDS with
mutation frequencies ranging from 1.85–16.36 % (Fig. 4c).
Importantly, a mutation with a frequency of 1.85 % was de-
tected in the DNA extracted from site 2 of the abovementioned
case underscoring the reliability of the VE1 staining. In the
remaining case, a mutation frequency of 0.79 % with only 29
reads containing the mutation was identified which, however,
was below our UDS threshold to be included as a true variant
(Fig. 4c). The positive control (co40) was successfully detected
at high frequency (29 %).
Comparision of results of IHC, SaS, and UDS in colorectal
carcinoma of the test cohort
As a comparison of VE1-IHC, SaS, and UDS, these 15 cases
and the positive control are shown in the Supplementary
Figure S1. The mutated base peak height from SaS was
comparable to the percentage of the mutation found by
UDS. However, all cases except for the positive control were
classified as wild-type when using SaS according to our
mutation detection threshold level explained in the
“Materials and methods” section. In contrast, SaS and UDS
results did not correlate in all cases with the VE1-IHC stain-
ing. This is mainly due to the heterogeneity of the tissue
(tumor/stromal/normal cells), which is shown for one case
(co25; Fig. 5). In this case, the TMA punches gave an IHC-
score 2 which matches the TMA extraction cores of the whole
tissue cut in Fig. 5. In contrast, the punches taken for DNA
extraction included one punch at a location with low tumor
content which might have resulted in the wild-type classifica-
tion by SaS and in the low percentage of mutated reads by
UDS (10.43 %).
Together, SaS and UDS detected BRAFV600E mutations in
37 (14%) and BRAF wild-type in 22 tumors (Fig. 3). The case
with VE1-IHC positivity and a BRAF mutation below the
Fig. 3 Flow chart of
immunohistochemistry (IHC),
Sanger sequencing (SaS), and
ultra-deep sequencing (UDS) on
test cohort
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detection limit of UDS (29 reads) was counted as false posi-
tive and included in the wild-type cases. The case with nega-
tive SaS and missing subsequent UDS was not counted for
further statistical analysis.
Statistical analysis showed a sensitivity of 100 % (95 % CI
90.75–100.00 %) and a specificity of 95.24 % (95 % CI
76.18–99.88 %) for VE1-IHC compared with combined re-
sults of both SaS and UDS as “gold standard” (see Table 2).
The PPVwas 97.44% (95%CI 86.52–99.94%) and the NPV
was 100.0 % (95 % CI 83.16–100.0 %) for VE1-IHC.
For SaS compared with combined results of both sequencing
methods (see Table 3) a sensitivity of 63.16 % (95 % CI 45.99–
78.19 %), a specificity of 100.0 % (95 % CI 83.16–100.00 %),
a PPV of 100.0 % (95 % CI 85.75–100.00 %), and a NPV of
62.86 % (95 % CI 40.7–75.35 %) was calculated.
Discussion
Our results show a very high reliability of the VE1 immuno-
histochemistry detecting BRAFV600E mutations in colorectal
carcinoma with a sensitivity of 100 % and a specificity of
95.24 %. Similar results were obtained in previous studies
using the VE1 antibody on different tumors like malignant
melanoma [24, 28], Langerhans cell histiocytosis [26], hairy
cell leukemia [18], papillary thyroid carcinoma [20, 23],
Fig. 4 Ultra-deep sequencing (UDS) of selected colorectal carcinoma cases
negative for BRAFV600E by Sanger sequencing but positive by VE1-IHC.
co40: positive control with a BRAFV600E mutation detected by Sanger
sequencing. a Total read count of wild-type and BRAFV600E mutated
sequences.b ReadswithBRAFV600E mutations. c Percentage ofBRAFV600E
mutated reads compared to total reads. d Sanger sequences of co40, co54,
and co31 with BRAFV600E mutations of 28.68, 16.36, and 1.85 % mutation
frequencies, respectively, assessed by UDS
Fig. 5 Tissue heterogeneity of
VE1-IHC stained colon
carcinoma tissue. Left panel :
whole tissue section. Right panel :
big cores taken for TMA
construction and smaller cores
punched for DNA extraction and
sequencing
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epithelial ovarian tumors [19, 25], and pulmonary adenocar-
cinoma [22].
The almost perfect interobserver agreement shows that the
interpretation of immunohistochemical staining results is quite
clear and simple in most cases. Using the well-defined criteria
(“diffuse and homogeneous granular cytoplasmic staining of
tumor cells”) for positivity, only few pitfalls, which have been
partly described previously [20, 21, 29, 30], occur. In colo-
rectal tissues, sometimes, a nuclear staining of normal epithe-
lial cells as well as an unspecific positivity of the intracellular
mucus of goblet cells and signet ring-like tumor cells can be
observed. Additionally, tumor-associated macrophages that
sometimes show a cytoplasmic granular positivity may be
difficult to differentiate from true-positive tumor cells.
According to the COSMIC database and literature, BRAF
mutations are found in about 4–16 % of CRC [3, 13, 31],
which fits very well with the frequency in our test cohort
bearing in mind that BRAFV600E changes counts for more
than 80 % of all BRAF mutations in CRC [9]. As we
performed Sanger sequencing only in 20 out of 225 VE1-
IHC-negative cases, we cannot exclude that some of the
remaining IHC-negative cases might have low frequency or
other BRAF mutations, as well, than BRAFV600E. However,
the aim of this study was rather to assess the detection limit of
the VE1 antibody than the detection limit of our UDS ap-
proach. The lower rate of BRAFV600E mutations in our anti-
body establishment cohort (4.4 %) can be explained by a
selection bias, while in contrast our test cohort consisted of
non-selected, consecutive colorectal carcinoma specimen.
Our study shows some limitations of Sanger sequencing
(SaS) in detecting BRAF mutations. It is well known that for
successful SaS, a minimal tumor cell amount of 10–20 % is
necessary. In summary, four (all VE1-IHC-score 2) out of 15
Sanger-negative cases had a tumor cell amount on TMA cores
below 30%. Three ones (all VE1-IHC-score 1), including that
one on which UDS could not be performed and that one with
UDS negativity due to low number of positive reads, showed
a heterogeneous VE1-IHC staining pattern. In a recent study
on mismatch repair protein-deficient colorectal carcinomas,
Capper et al. also reported one case with a high amount of
non-tumorous cells, which showed positive VE1-IHC and
negative Sanger sequencing and pyrosequencing [32].
However, in eight cases with homogeneous VE1-IHC posi-
tivity (three with score 1, five with score 2) and a tumor cell
percentage >60 %, SaS failed repeatedly to detect the BRAF
mutation. Thus, despite the fact that we used tumor punches
instead of whole sections for DNA extraction, which usually
results in a higher tumor cell load, SaS failed in 38 % of our
cases to detect the BRAFV600E mutation. One critical aspect of
punching the tumor area for DNA extraction is to allocate and
to hit the right area for punching. Such a case is shown in
Fig. 5, where one punch at a location with low tumor content
was included. This punch might have resulted in the wild-type
classification by SaS and in the low percentage of mutated
reads by UDS. Another case reflecting the same problem was
investigated by comparing sequencing data obtained from
DNA extracted from two different sites of a tumor which both
were positive for VE1-IHC. SaS detected a BRAFV600E mu-
tation only in one of these two sites. Subsequent UDS of the
Sanger-negative material revealed the same mutation at low
frequency. It may be speculated if VE1-IHC, which can also
highlight single tumor cells, was more sensitive detecting the
BRAF mutation than SaS or if VE1-IHC was false positive in
these tumor cells. The fact that UDS detected the mutation at
low frequency rather suggests a higher sensitivity of VE1-
IHC. Whether, in this case, the low mutation frequency was
due to the contamination of normal cells or due to intratumoral
heterogeneity remains elusive. Assuming the latter variant,
these results might reflect true intratumoral heterogeneity of
BRAF mutation, which has been reported as rare events
(1–3 %) in primary CRC [33, 34].
Another reason why, in our study, 38 % of the BRAF
mutations were missed by SaS might be the stringent selection
criteria we applied for classifying a mutation as true by SaS.
Retrospectively, one might adjust the detection threshold as in
most cases of the 15 previously classified wild-type cases a
mutated base peak was visible in SaS.
Our results agree with previous studies comparing SaS
with other sensitive detection methods like pyrosequencing
or deep sequencing. Guerra et al. reported a similar result
comparing BRAF mutational status of macrodissected papil-
lary thyroid carcinoma by SaS and pyrosequencing [35].
Thus, VE1-IHC seems to be sensitive enough to overcome
the problem of tissue and tumor heterogeneity. Taken together,
Table 2 Comparing results of VE1-immunohistochemistry with com-
bined results of Sanger and ultra-deep sequencing for BRAFV600E
mutations
Combined sequencing
results
Total
Negative Positive
VE1-immunohistochemistry Negative 20 0 20
Positive 1 37 38
Total 21 37 58
Table 3 Comparing results of Sanger sequencing alone with combined
results of Sanger and ultra-deep sequencing for BRAFV600E mutations
Combined sequencing results Total
Negative Positive
Sanger sequencing Negative 20 14 34
Positive 0 24 24
Total 20 38 58
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we demonstrate the high sensitivity and specificity of
detecting BRAFV600E mutations in colorectal carcinoma by a
new mutation-specific antibody. Our IHC results agree with
two other recently published studies investigating the VE1
antibody on CRC specimens [29, 36]. Both groups reported a
high concordance between VE1-IHC and pyrosequencing
[29] or multiplex allelic-specific PCR-based assay [36] as
reference methods. In contrast, a study by Adackapara et al.
[30] showed a much lower sensitivity (35 %) for VE1-IHC on
CRC specimen compared to pyrosequencing results. They
used a manual technique with overnight incubation for VE1-
IHC. Therefore, methodological differences could explain the
difference to ours and other studies.
Our study represents the first comparison between UDS
and VE1-IHC in CRC and we demonstrate a very high con-
cordance between UDS and VE1-IHC. In the light of the
relatively high costs and demanding infrastructure of ultra-
deep sequencing as well as the lower sensitivity of SaS, the
VE1-IHC, which can be performed routinely in probablymost
pathological institutes, seems to be a reliable, simple, and
cheap primary tool to analyze BRAFV600E status for diagnos-
tic, predictive, and prognostic purposes. Only VE1-negative
or equivocal cases may be further investigated by more sen-
sitive methods like ultra-deep sequencing.
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